BioCentury | Aug 10, 2015
Emerging Company Profile

New tac for modifying PAH

...factors that underlie the disease or its progression. Behind SPI-026, Selten has two preclinical programs: SPI-183...
...but with fewer side effects than tacrolimus. Selten has filed for a patent covering the SPI-183...
Items per page:
1 - 1 of 1